Somatic mutations of TP53, NOTCH1, MYC, and CDKN2A account for the aggressive phenotype of the DLBCL variant, which combines chemoresistance and rapid disease kinetics (Fig. 1) [4–6]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.